Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Amortization of Deferred Charges (2024 - 2025)

Historic Amortization of Deferred Charges for Arrowhead Pharmaceuticals (ARWR) over the last 2 years, with Q4 2025 value amounting to $14.9 million.

  • Arrowhead Pharmaceuticals' Amortization of Deferred Charges fell 816.96% to $14.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $62.0 million, marking a year-over-year increase of 14267.65%. This contributed to the annual value of $63.3 million for FY2025, which is 57967.16% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Amortization of Deferred Charges stood at $14.9 million for Q4 2025, which was down 816.96% from $14.6 million recorded in Q3 2025.
  • Arrowhead Pharmaceuticals' Amortization of Deferred Charges' 5-year high stood at $16.4 million during Q2 2025, with a 5-year trough of $9.3 million in Q3 2024.